A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The drug being studied, fesoterodine fumarate helps prevent the bladder neck opening at unwanted times and has been shown to help patients with overactive bladder syndrome pass urine less frequently than before treatment. It is postulated that this drug will also prove effective in elderly patients (aged > 65 years) and that the ability to change dose between 4 and 8mg will allow each patient to have an optimised treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Fesoterodine

Criteria

Inclusion Criteria:

• Male or female ≥65 years old.

• Overactive bladder symptoms for at least 3 months prior to study start.

• Eight or more micturitions per 24 hours as confirmed by diary records

Exclusion Criteria:

• Predominant Stress Urinary Incontinence

• Active or recurrent bladder infections

• Other bladder and genital conditions that could be the predominant cause of symptoms or interfere with treatment assessment and success.